(PharmaNewsWire.Com, December 22, 2020 ) The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.
Cell signaling is used to study signaling pathways of cells in drug discovery and therapeutic development, to distinguish drug resistance patterns in cancerous cells. It also identifies the major signaling pathways impacted by specific drug treatments. Cell signaling pathways—also called signal transduction pathways—act as connecting links between environmental stimuli and the corresponding cellular response. These signaling pathways mainly consist of proteins that can interact, move to specific locations, or be modified.
According to the new market research report “Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) – Global Forecast ” published by MarketsandMarkets™.
Revenue Growth Opportunities and Growth Drivers?
The Cell Signaling Market is expected to reach $3.51 billion, at a CAGR of 6.8%
Growth Driving Factors:
- Rising Incidence of Chronic Diseases - Availability of Funding for Cell-Based Research - Technological Advancements in Cell-Based Research Instruments - Growth of End-Use Industries
Market Growth Opportunities:
- Emerging Markets - Emergence of Microfluidics in Cell Biology Research
The key players in the cell signaling market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Abcam plc (U.K.), Miltenyi Biotec (Germany), Full Moon BioSystems, Inc. (U.S.), Cell Biolabs, Inc. (U.S.).
Geographical Regions Mapped in Report:
On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the cell signaling market. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region.
Based on product, the market is segmented into consumables and instruments. The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market. The increasing number of cell signaling research activities and rising incidence of chronic diseases are some of the major factors contributing to the segments large market share.
By pathway, is segmented into AMP-activated protein kinase (AMPK), Akt, ErbB/HER, Hedgehog (Hh), NF-êB, Janus kinase and signal transducer and activator of transcription (JAK/STAT), Notch, and other signaling pathways. The Akt pathway segment is estimated to account for the largest share of the market.
Based on signaling type, the market is segmented into paracrine, endocrine, autocrine, juxtacrine, and other signaling types (intracrine and neuronal signaling). The endocrine segment is estimated to account for the largest share of the cell signaling market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
